EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 117 filers reported holding EDGEWISE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $136,000 | +267.6% | 7,573 | +280.2% | 0.00% | – |
| Q1 2024 | $37,000 | -76.0% | 1,992 | -85.9% | 0.00% | – |
| Q4 2023 | $154,000 | +242.2% | 14,084 | +78.2% | 0.00% | – |
| Q3 2023 | $45,000 | +12.5% | 7,902 | +53.0% | 0.00% | – |
| Q2 2023 | $40,000 | +110.5% | 5,164 | +82.8% | 0.00% | – |
| Q1 2023 | $19,000 | -51.3% | 2,825 | -35.4% | 0.00% | – |
| Q4 2022 | $39,000 | +225.0% | 4,372 | +260.7% | 0.00% | – |
| Q3 2022 | $12,000 | +50.0% | 1,212 | +19.1% | 0.00% | – |
| Q2 2022 | $8,000 | -74.2% | 1,018 | -68.5% | 0.00% | – |
| Q1 2022 | $31,000 | -87.0% | 3,227 | -79.4% | 0.00% | – |
| Q4 2021 | $239,000 | +895.8% | 15,652 | +1017.2% | 0.00% | – |
| Q3 2021 | $24,000 | +33.3% | 1,401 | +66.0% | 0.00% | – |
| Q2 2021 | $18,000 | – | 844 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |